维持性血液透析患者骨保护蛋白及核因子κB受体活化子配体的研究被引量：2

原文传递

导出

摘要肾性骨病是维持性透析患者最常见的并发症之一。既往研究认为，肾性骨病的发病机制主要与继发性甲状旁腺功能亢进、1，25-（OH）2D，不足、钙磷代谢紊乱、酸中毒及铝中毒等因素有关，但临床上肾性骨病的发病并不能完全用上述因素来解释。

作者刘双信史伟梁馨苓李珩叶智明王文健何朝生胡湘明章斌彭炎强梁永正

机构地区广东省人民医院肾内科

出处《中华肾脏病杂志》 CAS CSCD 北大核心 2006年第3期170-171,共2页 Chinese Journal of Nephrology

基金广东省自然科学基金(020426) 广东省重点攻关项目科研基金(2004B30701006) 广州市重点攻关项目(2005Z3-E0121) 广东省卫生厅基金(A2005036)

关键词维持性血液透析患者肾性骨病继发性甲状旁腺功能亢进活化子 B受体核因子维持性透析患者配体白及保护

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献7

1Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell,1997,89:309-319.
2Hsu H,Lacey DL,Dunstan CR ,et al.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Natl Acad Sci USA,1999,96:3540-3545.
3Coen G,Ballanti P,Balducci A,et al.Serum osteoprotegerin and renal osteodystrophy.Nephrol Dial Transplant,2002,17:233-238.
4许多荣,余学清,方荸荠.甲状旁腺激素在体外对破骨细胞分化及骨重吸收能力的影响[J].中华肾脏病杂志,2005,21(4):186-190. 被引量：14
5Pei Y,Hercz G,Greenwood C,et al.Renal osteodystrophy in diabetic patients.Kidney Int,1993,44:159-164.
6Avbersek LI,Balon BP,Rus I,et al.Increased bone resorption in HD patients:is it caused by elevated RANKL synthesis?Nephrol Dial Transplant,2005,20:566-570.
7Huang JC,Sakata T,Pfelger LL,et al.iPTH differentially regulates expression of RANKL and OPG.J Bone Miner Res,2004,19:235-244.

二级参考文献14

1Fong AM, Erickson HP, Zachariah JP, et al. Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation. J Biol Chem, 2000,75: 3781-3786.
2Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the members of the tumor necrosis factor receptor and ligand fanilies. Endocr Res, 1999,20: 345-357.
3Duorong Xu,Zhenqi Shi,Xu Feng,et al. Development of a chimacric receptor approach to study signaling by tumour necrosis factor family members. Biochem J, 2004,383:219-225.
4Wei L, Duorong X, Hongmei Y, et al. Functional identification of three RANK cytoplasmic motif mediating osteoclast differentiation and function. J Biol Chem, 2004,279:54759-54769.
5Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteogenesisinhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad Sci UAS, 1998,95:3597-3602.
6Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the members of the tumor necrosis factor receptor and ligand families. Endocr Res, 1999,20: 345-357.
7Hofbauer L, Khosla S, Dunstan C, et al. The roles of osteoprotegerin and osteoprogerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res,2000, 15:2-12.
8Shi W, Michael WH, Steven L, et al. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and Mitogen-activated protein kinase signaling. J Biol Chem,2002,277: 6622-6630.
9Simonet W, Lacey D, Dunstan C, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997,89: 309-319.
10Schiller P, Ippolito G, Roos B, et al. Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment.J Bone Miner Res, 1999,14: 1504-1512.